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Intraepithelial neoplasms of the uterine cervix
Cervical intraepithelial neoplasms
The cervical intraepithelial neoplasms (CINs) are ab-
normalities of the squamous ectocervical epithelium.  The
first group consists of squamous intraepithelial lesions of low
histological stage (LSIL) and includes flat condyloma and
CIN I, while the second group consists of squamous intra-
epithelial lesions of high histological stage (HSIL) including
CIN II and CIN III.
Epidemiological data
Epidemiological data on the frequency of the incidence
and detection of these changes are scarce and varying, so
they cannot be accepted with certainty. It is only confirmed
that these changes are being increasingly detected and what
is more, in the younger age groups. This is explained by new
knowledge of the etiologic factors of these changes, which
makes them classified in the group of sexually transmitted
diseases, as well as by altered behavior regarding to sexual
sphere
 1–5.
Risk factors
Human papilloma viruses (HPV) play a significant role
in the development of cervical neoplasms 
2, 6, 7. The most im-
portant issues are a promiscuous behavior of both women
and men, early sexual activities, poor sexual hygiene with
frequent infections of the genital organs, failure to use barrier
methods of contraception, etc. 
8. There are other risk factors
contributing to initiation and development of pathological
event. They are designated as cocarcinogens and such as im-
pair immunity, smoking, genital infections caused by other
agents (genital herpes virus, HIV, cytomegalovirus, chla-
mydia trachomatis) as well as some medications (cytostatics,
immunosuppressants) 
6, 8–11.
Molecular biology examinations verified the presence
of specific viral DNA sequences (E6 and E7) integrated into
the genome of the atypical cervical epithelial cells. It is pos-
sible to document it in over 80% of intraepithelial neoplasms
and in over 98% of cervical cancers 
7. Presently, it is known
that less than 2% of cervical cancers are negative to HPV
DNA, provided that they were caused by, at that time, unde-
tected types of viruses, or HPV genetic material was lost in
the process of oncogenesis 
11. Pathogenetic mechanism of
malignant cell transformation has been elucidated, as well.
Viral genome has circular shape and as such enters the host
cell through the skin or mucosal membrane microabrasions;
or, in case of the uterine cervix, through the cells of basal or
parabasal layer within the transformation zone. There is a
continuous mitotic activity in these layers, and these are the
target cells for HPV infection of the cervix. Virus entry into
the cell is the initial event, which may, upon a series of other
intracellular events, result in development of neoplasia. Viral
DNA, immediately upon the entry of viral particle in the host
cell, is being freed from capsid and travelling to the cell nu-
cleus. Herein, the circular viral genome will be placed epi-
somally, not inducing any cytopathogenetic effect. It will be
a latent infection and it may remain as such. It has been
proved that about 10% of female population has latent HPV
cervical infection, and no signs of disease. However, if so far
undefined factors designated as cocarcinogens, caused
breakage of the viral genome ring, its sequences would be
freed and the process of mutagenesis would be initiated. The
sequences E1 and E2 of the viral genome lose control over
the sequences E6 and E7, which are then integrated into the
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genes of host cells p53 and pRB, thus breaking the normal
control mechanisms of the cell growth. The result of these
events is the alteration of the host cell structure, which ac-
quires proliferative properties, characteristic for oncogenesis.
The lesion developed in this way is, as a rule, monoclonal,
meaning that it originated from a single cell in which the
process originally started.
Infections with HPV 16 and 18 and other oncogenic
types are more likely to persist than infections with low-risk
HPV types. In women 15–25 years of age, ~80% of HPV in-
fections are transient. In older women, cervical HPV infec-
tions are more likely to persist. Persistent oncogenic HPV in-
fection is a precursor to invasive cervical cancer. The risk
starts from sexual debut and continues through out life. Inci-
dent infection of oncogenic types is estimated to be 5.3%
(range: 5%–10%) in women 25–55 years of age. Immune
function declines with aging resulting in a decreased capacity
to respond to both new and previously encountered infec-
tions. Up to 80% of sexually active women are infected with
HPV at some point of their lifetime. Prior HPV infection
may not always induce sufficient immunity to prevent subse-
quent infection. Knowing this, vaccination against HPV
16/18 is very important 
11–13.
It is also known that the process of oncogenesis is rela-
tively slow and develops principally as a biological contin-
uum, from the initial intraepithelial neoplasm to the invasive
cancer. It usually lasts several years, but there have been some
described cases with a 6-month period of genesis. A progres-
sive course of the disease is mostly caused by high oncogenic
potential viral infection, although it may be significantly af-
fected by cocarcinogens, particularly the immune status of a
patient. According to different and numerous results of studies,
a significant number of HPV infections regresses spontane-
ously or persists in a latent stage, while lesser number leads to
cervical neoplasms. Already developed cervical intraepithelial
neoplasm may also regress spontaneously, but the possibility
for this to happen would be lesser if the neoplasm stage was
higher. For instance, the cancer in situ will progress into inva-
sive cancer in about 70% of cases 
14–17.
Symptomatology
Symptoms of CINs are practically absent, so they are
referred to as asymptomatic stage of disease.
Diagnostics
The diagnosis of CIN is based on the methods of HPV
testing, cytology, colposcopy and histopathological exami-
nation of the bioptic tissue specimen. Due to its simplicity
and cost-effectiveness, cytology is the most often used diag-
nostic method, representing the basis of screening program
in many countries worldwide. It must be pointed out that its
sensitivity in discovering the intraepithelial stages of disease
is limited. In histologically verified CIN, the percentage of
false negative results of cytodiagnostics is considerable. This
percentage is higher if the stage of the intraepithelial neo-
plasm is lower, therefore, the normal cytological finding may
be seen in the majority of the initial and even mid-severe in-
traepithelial lesions 
7. Other than cytodiagnostics, colpo-
scopy is another basic method for detection of the cervical
neoplasms, characterized by considerably higher sensitivity
of detecting the lowest stages of disease 
18.
The baseline of colposcopy is in recognition of patho-
logical changes of the cervical epithelium pathognomonic for
CIN, which are based on significant protein increase in dys-
plastic cells and considerable loss of glycogen, as well as on
the changes of the stromal vascular net regarding the num-
ber, appearance and capillary arrangement. Upon the appli-
cation of 3% acetic acid and Lugol’s solution on the cervix,
these changes are, under colposcope, presented with specific
colposcopic images.
CIN undergoing a colposcopic examination are mani-
fested as characteristic pathological pictures of acetowhite
epithelium, mosaic, punctations, leukoplaques, negative
epithelium iodine or atypical blood vessels. Qualitative ex-
tent of a change and their associated manifestations are pro-
portional to stage of the intraepithelial neoplasm. They are a
sign of the pathological events in the epithelium and need to
be histologically explained 
19.
Besides classical colposcopy, recently the method of
microcolpohysteroscopy has been used for CIN diagnostics.
For verification and determination of a pathological
change extent detected by HPV testing, colposcopy and/or
cytological examination, it would be necessary to perform
biopsy of the exocervix and endocervical curettage if the
change extended to cervical channel. The biopsy is targeted,
colposcopy-assisted, and a specimen obtained from the most
evident epithelial changes. It is not rare that multiple biopsies
are required, so the pathologist will be supplied with most
representative bioptic tissue specimens for histological
analysis. A resulting finding will make the final diagnosis of
a pathological change and represent the basic parameter for
decision-making on the future treatment according to current
protocols 
19.
Cervical glandular intraepithelial neoplasm
Intraepithelial neoplasm in the cervical channel origi-
nates from cylindric epithelium. In recent decades, it has
been detected more frequently, probably due to better diag-
nostic procedures, including the endocervical smear, HPV
testing and the utilization of microcolpohysteroscopy. In
comparison to CIN, cervical glandular intraepithelial neo-
plasm (CGIN) is being detected relatively late, not uncom-
monly in the invasive disease stage. HPV is a major etiologi-
cal factor.
Prognosis
Considering the prognosis of these pathological
changes, it is worthwhile mentioning that their biological be-
havior is unpredictable. The presence of HPV oncogenic
types in the cells of intraepithelial change multiplies the pos-
sibility of its progressive development to invasive disease.
The principle of preventive actions should be respected, not
allowing for already diagnosed intraepithelial change to de-
velop into invasive cancer 
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Treatment
In LSIL pathological changes, only cytological and
HPV typing will be sufficient. If the change persisted, it
would be treated by some of destructive techniques, with
previous endocervical curettage. If the oncogenic HPV types
were detected in a LSIL pathological change, the typing
would be repeated in 6 months, and if the infection was still
persistent, the change would be treated by some of destruc-
tive techniques. If histological examination of a bioptic
specimen reveals pathological HSIL change, the treatment
will include excision techniques. Histological examination of
excised tissue confirms the excision effect and depending
upon the outcome, regular follow-up or additional excision
treatment will be the options 
12.
Treatment of LSIL presently involves several tech-
niques, which, on one hand, should enable a complete cure,
and on the other, preserve, to the largest extent possible, the
function of the uterine cervix for future conception and birth
since very young women are often in question. The tech-
niques currently available for their treatment are described as
destructive techniques, such as: laser vaporization, cryother-
apy, cold coagulation and electrocauterization. They may be
carried out in hospitals or on outpatient basis, under general
or local anesthesia 
21.
Laser vaporization
Laser vaporization is performed by means of CO2 laser,
which emits a beam of 10.6 μm wave length. The output
temperature at the laser beam and tissue contact is over
100 ºC, resulting in vaporization of the extra- and intracellu-
lar fluid and carbonization of the cell structures and intra-
cellularly located virus particles. Postoperative complications
as infection or hemorrhage are extremely uncommon, and
the effect of cure after just one treatment is very high, ac-
counting for 96%–98% 
20, 22.
This method is advantageous over other techniques by
extremely good postoperative regeneration of vaporized tis-
sue, what significantly contributes to rapid restoration of
anatomic and functional integrity of the cervix.
Cryotherapy
The method of cryotherapy is based on cervical tissue
freezing by liquid nitrogen, which pressurized passes through
special tubes leaning against the cervical tissue. The best de-
structive effect of pathological change is achieved by
“freezing-defrosting-freezing” technique 
22.
Cold coagulation
A special Semm coagulator is used for performance of
this technique. It achieves tissue destruction by heat, which
is transferred via a thermic tube to the uterine cervix. Upon
positioning a tube on the cervix, the device is being acti-
vated and the temperature of 120 ºC on the top of the tube
will be reached in 15–20 seconds. For destruction of
pathological change in the uterine cervix, it is enough to
keep on leaning the tube against the cervical tissue for two
minutes 
22.
Electrocauterization
This method is designated as electrodiametry as well,
and based on the effect of electrical power on pathological
cervical tissue. The power of 40W–50 W is used, which is
transferred to the tissue by means of special tubes in the
shape of a needle or small ball. The procedure is painful, so
it is performed in general anesthesia, which together with
some other limitations, reduces its broad utilization.
Cervical HSIL changes, involving CINs of stages II and
III (CIN II and CIN III), call for treatment using these meth-
ods, which will enable a partial cervical removal or extirpa-
tion of the whole uterus and its postoperative histological
analysis. These are so-called excision methods, including the
following: scalpel conization, laser conization, “loop” exci-
sion and hysterectomy 
22.
Scalpel conization – It is a classical excision technique,
where a part of the cervix is excised by scalpel in the shape
of cone or cylinder, depending upon the localization of a
pathological change. Surgery is carried out in general anes-
thesia, with different modes of hemostasis, while the suture
technique is completed by Sturmdorf. The effectiveness of
surgery, i.e. elimination of the pathological HSIL as a whole,
varies, while the percentage of the incomplete removal has
been reported in 1% to 13% what may be verified by addi-
tional histopathological examination of the removed cone 
22.
Laser conization – Comparing to classical techniques, it
differs in that cervical incision is made by a 30 W–60 W la-
ser beam. As in scalpel excision, the cervical tissue is ex-
cised in the shape of the cone or cylinder, depending upon
the localization of a pathological change.
With intracervical application of vasoconstrictors, the
surgery is performed without bleeding, what excludes the
need for hemostatic sutures. This is the core of the absence
of subsequent scarred deformities of the cervical remnant
and preservation of its functional integrity. It is especially
valuable in operations of young women, whose fertile ability
should be spared. Apart from the above-mentioned, laser
conization has other advantages over classical methods. It
may be carried out on outpatient basis, under local anesthe-
sia, and the proportion of the intraoperative and postopera-
tive complications is lesser as compared to other tech-
niques 
22.
“Loop” excision – This technique requires a generator,
a power source and a series of thin wire loops, circular or
rectangular in shape. By its holder, the loop is passed
through the tissue of the uterine cervix, while the electric
power running through the loop is being warmed up, thus ac-
complishing the effect of tissue cutting. The hemorrhage is
stopped by means of the ball electrode.
The method is simple to perform, and its application is
restricted by pathological process localized high up in the
cervical channel, as well as by immensely spread ectocervi-
cal changes, which cannot be excised by a single cut.
In so far described excision techniques of management
of cervical HSIL, it is necessary to point out the need for cu-
rettage of the cervical channel residue and histological veri-
fication of the respective bioptic tissue specimen 
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Postoperative controls
In addition, it is important to emphasize the need for
postoperative controls, due to low but always present risk of
residual or recurrent disease.
If the excised cervical tissue histological examination
show that a pathological change had been removed in toto, it
is be followed by a cytologic 6-month follow-up and HPV
testing subsequently, once a year. If the lesion has not been
removed completely, that is, it involves the resection margin
of the cone as well, it is possibile to opt for cytological and
colposcopic (histological) monitoring for 4–6 month, with
HPV-typing in 6 months. Moreover, repeated conization
would be another options, and if not feasible or HSIL change
recurred, the hysterectomy should be done 
12, 20–27.
Vaginal intraepithelial neoplasms
Intraepithelial neoplasms (VAINs) of the vagina are
less frequent than those of the cervix, accounting for 0.4%–
0.5% of all intraepithelial neoplasms of the female lower
genital tract. In relation to epithelial involvement by atypical
cells, they are classified in a similar way as CIN, i.e. to
VAIN I – with changes in the lower third of the epithelium,
VAIN II – pathological change involves lower two-thirds of
the epithelium and VAIN III – atypical cells involved the full
epithelial thickness. The risk and etiological factors of the
VAIN etiology are the same as for CIN, with predominant
role of the human papilloma virus infection. For this reason,
VAIN is most commonly discovered in patients treated for
CIN or cervical cancer. The association with cervical neo-
plasms is the reason for its presentation in the upper third of
the vagina. In further course, VAIN may tend to regress
spontaneously, persist in the same stage for a long period of
time or progress into cancer. Such progression is less fre-
quent than in CIN, and sometimes it may manifest as spread
of neoplastic process from cervix to vaginal fornix. The di-
agnostics of VAIN, which is typically asymptomatic disease,
is based on cytological examination, colposcopy and his-
tological verification of a bioptic tissue specimen. The treat-
ment of VAIN may be completed by the laser technique,
cryotherapy or electrocauterization. Given that VAIN fre-
quently localized in the vaginal fornices is very difficult to
access, laser technique, which appeared to yield good results,
is preferential. If VAIN was present together with cervical
neoplasm, its treatment would include partial vaginectomy,
in the same surgical act applied for cervical malignancy.
Therapeutical treatment of VAIN will be followed by regular
controls in 6 months as it was in CIN case
 28, 29.
Vulvar intraepithelial neoplasms
Vulvar neoplasms (VINs) may appear in the squamous
epithelium designated as VIN as well as intraepithelial neo-
plasms not originating from squamous epithelium.
This disorder is classified into two main groups: 1)
VIN, usual type, which encompasses the former subcatego-
ries of VIN, warty type; VIN, basaloid type, and VIN, mixed
/ warty, basaloid / type; 2) VIN, differentiated type, which
encompasses the former category simplex type.
Rare cases that do not fit into these categories are
termed “unclassified type“.
The term VIN is limited to histologically high-grade
squamous lesions for which treatment is indicated to prevent
progression to cancer.
VIN is most commonly seen in immunocompromised
and postmenopausal women, but the incidence is increasing
among healthy patients in younger age groups. Risk factors
are similar to those observed for CIN. It is estimated that
HPV infection is the major factor here, and it appears to be
particularly often with the type 16. The commonest VIN lo-
calization is in the region of clitoris and lower third of the la-
bia major and minor. It is often not manifested by symptoms,
but some women may experience sense of discomfort, itch-
ing or burning sensation. Its evolution is very slow, and
therefore, it is detected only a few years after the manifesta-
tion of symptoms. Clinically, i.e. vulvoscopically, VIN may
be presented as a flat, elevated or papillary change, whitish,
brown or red color with absent or present blood vessels,
which may have atypical appearance. It is often multifocal or
associated with VAIN or CIN. In addition, it may be associ-
ated with condylomatous growths, especially the bowenoid
VIN type, which is more often presented in younger women.
Basaloid VIN is more common in elderly women, has higher
malignant potential and is not manifested concurrently with
condylomata 
17.
The change may vary, to a large extent, in surface, color
and focality. Vulvoscopic examination are used to determine
the exact location of the change for as adequate as possible
biopsy. Histopathological examination of biopsy tissue is the
only method to confirm the VIN diagnosis, considering the
great similarity with many other skin diseases. Biopsies must
often be multifocal and best performed by a special key exci-
sion instrument. The scalpel excision biopsy can also be
done under local anesthesia.
The treatment of VIN involves different modalities in-
cluding topical chemiotherapy, imiquimoid, CO2 laser abla-
tion, surgical exision, cryotherapy, loop electrosurgical exci-
sion procedure (LEEP), cavitron ultrasonic aspiration
(CUSA) and interferon injections
 30.
Imiquimod, an immune response modifier, has been
successful in the treatment of external genital and perianal
warts caused by low risk HPV, usually types 6 or 11. The
drug antiviral and antitumor properties are thought to be due
to its induction of cytokines, which stimulate a T-helper 1 or
cell-mediated immune response. Recently, it has been shown
that imiquimod may be potentially effective in the treatment
of genital intraepithelial neoplasia caused by high-grade
HPV 
30.
Aldara Cream activates immune system to help body
fight certain skin diseases, including actinic keratosis, super-
ficial basal cell carcinoma and external warts. The most
common side effects associated with using Aldara Cream in-
volve skin reaction in the application area.
Given very long VIN evolution, lasting for years and
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been described (but not in high percentage – mainly seen in
young women and is often related to pregnancy), give us op-
portunity to take the expectational standpoint and control the
changes on regular basis only. In so far the signs of progres-
sion are noted during a follow-up (aneuploidy, presence of
oncogenic HPV types), or in older patients, or in immuno-
compromised patients, radical methods of treatment should
be considered. These include wide local scalpel or laser exci-
sion (for nonhairy vulvar regions), simple vulvectomy or
vulvectomy with grafting, in case of changes found on a
broad surface in younger patients. VIN management has also
included some medicaments (5-FU, dinitro chloride-benzene,
interferon), but without any encouraging results. Upon com-
pletion therapy, the regular control are necessary, not only of
the vulva but also the entire lower genital tract, taking into
account the identical features of the intraepithelial neoplasms
which may manifest concurrently on these localizations. The
patients with a previous history of cervical cancer also
showed identical viral integration sites between their vaginal
and/or vulvar lesions and their previous cervical tumors.
Perhaps a large majority of high-grade lesions in the female
genital tract emerge as monoclonal cell populations derived
from the cervical transformation zone. Owing to this fact, we
must consider vaccine efficacy in preventing cervical lesions
in our estimate of how vaginal and vulvar epidemiology may
change 
23, 24, 27, 30, 31.
Out of VIN, not originating from the squamous epithe-
lium, worth-mentioning are Paget’s disease and melanoma in
situ.
Conclusion
Great importance is ascribed to prevent and detect and
well-timed treatment of these asymptomatic lesions because
it is the most efficient way of fighting against the malignant
diseases of the uterine cervix, vagina and vulva. It is best
achievable by vaccination and systemic screening of female
population.
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